Objectives:

to analyze the safety of biologic therapies (FAME-b) in the Paraguayan patient cohort of the BIOBADAGUAY registry (Paraguayan-Uruguayan registry of adverse events (AE) in patients with inflammatory rheumatic diseases.

Material and Methods

: BIOBADAGUAY is a registry to prospectively evaluate the efficacy and safety of b-DMARDs. The complete methodology is available at https://biobadaguay.ser.es. Variables associated with the safety of therapies were used for the present study. The incidence of EA was calculated as incidence rate (IR) per 1000 patient-years, with 95% confidence intervals (CI) and Poisson regression for the incidence rate ratio (IRR).

Results:

We analyzed 696 patients (71.3% women) with 1077 predominantly mild AE (88.6%). The overall incidence was 323.8 per 1000 patient-years. Infections were the most frequent AA (55.3%). Anti-TNF treatment was associated with a lower incidence of EA, while second and subsequent lines of treatment were associated with more AE.

Conclusions:

This study has provided valuable data on the safety of FAME-b in a cohort of Paraguayan patients with inflammatory rheumatic diseases. Most of AEs were mild and infectious processes were the most frequent AE. It is important to continue with these registries to contribute to a rigorous and permanent control of this patient population.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )